Citi analyst Samantha Semenkow initiated coverage of Amicus (FOLD) with a Buy rating and $17 price target The company is focused on commercializing rare disease therapies, the analyst tells investors in a research note. The firm believes Galafold and PomOp are positioned for combined sales of over $1B in 2028.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus price target raised to $19 from $18 at JPMorgan
- Amicus price target raised to $11 from $9 at Goldman Sachs
- Amicus Therapeutics Reports Strong Q3 2025 Results
- Amicus Therapeutics Reports Strong Q3 Earnings Growth
- Amicus’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Analyst